February 20, 2013 source: the original post by Ed Silverman appeared in Pharmalot As drug development and diagnostics increasingly converge, the advent of personalized medicine is increasing all the time. Of course, we are not quite there yet, but the advent of electronic medical records and the genome are inching us closer all the time. But […]Read More
Bloomberg reporter Ryan Flinn recently wrote an article on Brain Scans Seek Best Drug Match for Depression Patients. The article summarizes some of the technologies that are being used by clinicians to assist in diagnosis and treatment of depression, and focused on technologies provided by two companies. The first company profiled uses a technology that matches […]Read More
March 7, 2012 source: Angel Capital Association (ACA) AssureRx Health, Inc. Receives 2012 ACA Luis Villalobos Award for Innovation Angel Capital Association Recognizes Company For Industry-leading Personalized Medicine Solution Hats off to one of my portfolio companies, AssureRx today received the the 2012 Luis Villalobos Award from the Angel Capital Association (ACA), the trade association of […]Read More
January 18, 2012 source: MedCity News Personalized medicine company AssureRx Health has released the next-generation version of its genetic screening test for psychiatric drugs. The Cincinnati-area company’s GeneSightRx test, which helps doctors pick the right psychiatric drugs for patients based on their genes, was launched in 2009. The test uses a cheek swab, mathematical […]Read More
September 9, 2011 source: originally published in the San Francisco Business Times Gene Security Network’s race to develop safer, more accurate prenatal test is all business for Matt Rabinowitz — and it’s personal. A relative of Rabinowitz, Gene Security Network’s CEO, took a blood test for the likelihood of Down’s syndrome in her unborn baby and […]Read More
Claremont Creek Ventures portfolio company Gene Security Network (GSN) achieved a technical breakthrough that even Dear Abby can crow about. Never before, have scientists and clinicians been about to measure fetal DNA in a pregnant woman’s blood with enough accuracy to determine paternity or relevant information about the baby in utero — until now. If […]Read More
Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.